Key Points
- Insider sale: Centessa insider Mario Alberto Accardi sold 10,000 shares on Dec. 8 at $30 each for $300,000, cutting his stake to 188,801 shares (a 5.03% reduction); he also sold 8,000 on Oct. 27, 8,172 on Sept. 16 and 7,000 on Sept. 9.
- CNTA opened at $29.50 and is trading near its 52‑week high of $30.58 with a $3.97 billion market cap; the company reported quarterly EPS of -$0.41 (missing estimates) and is forecast to post -1.6 EPS for the fiscal year.
- Analyst sentiment is positive overall—average rating is "Buy" with an average target of $35.50—and several firms (B. Riley, Guggenheim) have recently raised targets into the low $40s.
Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA - Get Free Report) insider Mario Alberto Accardi sold 10,000 shares of the business's stock in a transaction dated Monday, December 8th. The shares were sold at an average price of $30.00, for a total transaction of $300,000.00. Following the transaction, the insider owned 188,801 shares in the company, valued at $5,664,030. This represents a 5.03% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.
Mario Alberto Accardi also recently made the following trade(s):
- On Monday, October 27th, Mario Alberto Accardi sold 8,000 shares of Centessa Pharmaceuticals stock. The shares were sold at an average price of $25.00, for a total value of $200,000.00.
- On Tuesday, September 16th, Mario Alberto Accardi sold 8,172 shares of Centessa Pharmaceuticals stock. The stock was sold at an average price of $21.40, for a total value of $174,880.80.
- On Tuesday, September 9th, Mario Alberto Accardi sold 7,000 shares of Centessa Pharmaceuticals stock. The stock was sold at an average price of $20.00, for a total value of $140,000.00.
Centessa Pharmaceuticals Trading Down 1.4%
CNTA opened at $29.50 on Tuesday. The company has a quick ratio of 10.57, a current ratio of 10.56 and a debt-to-equity ratio of 0.36. Centessa Pharmaceuticals PLC Sponsored ADR has a 52 week low of $9.60 and a 52 week high of $30.58. The stock has a market cap of $3.97 billion, a PE ratio of -16.12 and a beta of 1.55. The business has a 50 day moving average of $25.19 and a 200-day moving average of $19.36.
Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last posted its quarterly earnings data on Wednesday, November 5th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.39) by ($0.02). Equities research analysts predict that Centessa Pharmaceuticals PLC Sponsored ADR will post -1.6 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Centessa Pharmaceuticals
A number of hedge funds have recently added to or reduced their stakes in CNTA. Russell Investments Group Ltd. bought a new position in Centessa Pharmaceuticals in the 1st quarter valued at approximately $3,273,000. Caitong International Asset Management Co. Ltd lifted its holdings in shares of Centessa Pharmaceuticals by 15,209.5% during the first quarter. Caitong International Asset Management Co. Ltd now owns 3,215 shares of the company's stock valued at $46,000 after purchasing an additional 3,194 shares in the last quarter. Regents of The University of California purchased a new stake in shares of Centessa Pharmaceuticals during the first quarter valued at $1,177,000. Lord Abbett & CO. LLC increased its holdings in Centessa Pharmaceuticals by 1.3% in the 1st quarter. Lord Abbett & CO. LLC now owns 446,196 shares of the company's stock worth $6,416,000 after buying an additional 5,701 shares in the last quarter. Finally, Fox Run Management L.L.C. bought a new stake in Centessa Pharmaceuticals in the 1st quarter worth about $160,000. 82.01% of the stock is currently owned by hedge funds and other institutional investors.
Analysts Set New Price Targets
Several brokerages recently issued reports on CNTA. Weiss Ratings reiterated a "sell (d-)" rating on shares of Centessa Pharmaceuticals in a research note on Wednesday, October 8th. Wall Street Zen raised shares of Centessa Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Monday, October 27th. B. Riley boosted their price target on Centessa Pharmaceuticals from $33.00 to $42.00 and gave the stock a "buy" rating in a research report on Monday, December 1st. Guggenheim upped their price target on Centessa Pharmaceuticals from $28.00 to $43.00 and gave the stock a "buy" rating in a research note on Tuesday, November 18th. Finally, Oppenheimer assumed coverage on Centessa Pharmaceuticals in a research note on Friday, August 29th. They set an "outperform" rating and a $40.00 price objective for the company. Two investment analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Buy" and an average target price of $35.50.
View Our Latest Report on CNTA
About Centessa Pharmaceuticals
(
Get Free Report)
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
